{
  "pmcid": "12514961",
  "sha256": "ffc1d257a2a97e926df425573b3f81fb63453711bf1e7a3ccb1884e83b05085b",
  "timestamp_utc": "2025-11-09T23:43:03.115579+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.630732838589982,
    "reading_ease": 31.511182745825607,
    "word_count": 245
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Liposomal Bupivacaine in Thoracic Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "single-center, double-blind, randomized, parallel-controlled trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "102 patients scheduled for elective thoracoscopic surgery at the Affiliated Hospital of Qingdao University"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomized 1:1 to receive thoracic paravertebral block with LB (6.67 mg/mL) or ropivacaine hydrochloride (RH; 0.33%)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assessed the impact of liposomal bupivacaine (LB) on postoperative opioid consumption and recovery in patients undergoing thoracic surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was opioid consumption within 72 hours postoperatively."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was achieved using fixed block randomization with allocation concealment via sealed opaque envelopes."
      },
      "Blinding": {
        "score": 3,
        "evidence": "Blinding was maintained for participants, clinicians, and outcome assessors."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "From November 1, 2024, to March 10, 2025, 102 patients were randomized (LB group, n = 51; RH group, n = 51)."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "One patient was excluded, resulting in 101 patients analyzed."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "LB significantly reduced 72-hour opioid consumption compared to RH (mean difference = –181.4 mg; 95% CI: –232.8, –130.0 mg; P < 0.001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "No significant differences in adverse events were observed between groups."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial Registration: ChiCTR2400091217."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: Not specified."
      }
    },
    "total_score": 24,
    "max_score": 25
  }
}